Antiangiogenic drugs: insights into drug development from endostatin, avastin and thalidomide.
Holaday
John W
JW
john.holaday@qrxpharma.com
Berkowitz
Barry A
BA
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D055808:Drug Discovery / Q000266:history*; D043169:Endostatins / Q000627:therapeutic use; D049673:History, 20th Century; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D013792:Thalidomide / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D043169:Endostatins; D000068258:Bevacizumab; D013792:Thalidomide